➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKinsey
Dow
Boehringer Ingelheim
Harvard Business School

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Patent: 10,149,876

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,149,876
Title:Tripterygium wilfordii extracts to overcome chemotherapy resistance
Abstract: The invention provides extracts and compositions derived from Tripterygium wilfordii for overcoming drug resistance in cancer therapy. This invention relates to organic solvent extracts of T. wilfordii and their use in cancer treatment, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods of treating a cancer are disclosed. The method administers to a patient in need thereof a combination of (a) an organic solvent extract of T. wilfordii and (b) a chemotherapeutic drug. The organic solvent extract of T. wilfordii (a) and chemotherapeutic drug (b) are administered in a combined amount effective to treat the cancer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug (b) alone. Also disclosed are chemotherapeutic compositions comprising a combination of (a) an organic solvent extract of T. wilfordii and (b) a chemotherapeutic drug, wherein (a) and (b) are administered in a combined amount effective to treat the cancer; and a pharmaceutically acceptable carrier.
Inventor(s): Chow; Moses Sing Sum (Chino Hills, CA), Huang; Ying (Arcadia, CA), Wang; Jinghua Jeffrey (Arcadia, CA), Ravula; Ranadheer (Atlanta, GA), Wang; Zhi Jun (Chino Hills, CA)
Assignee: WESTERN UNIVERSITY OF HEALTH SCIENCES (Pomona, CA)
Application Number:14/422,216
Patent Claims:see list of patent claims

Details for Patent 10,149,876

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial WESTERN UNIVERSITY OF HEALTH SCIENCES (Pomona, CA) 2039-02-26 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial WESTERN UNIVERSITY OF HEALTH SCIENCES (Pomona, CA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKinsey
Johnson and Johnson
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.